Abstracts tagged "COVID-19"

Abstract Number: 1601 • ACR Convergence 2021
Satisfaction with Telemedicine in Immunosuppressed Children and Young Adults with Autoimmune Disease During the COVID 19 Pandemic: Are Their Needs Really Met? Preliminary Data from a Single Institution
Lakshmi Moorthy¹, Lauren Freidenrich¹, Lisa Mikesell², Sarah Fadem², Vikram Bhise¹, Richard Brodsky¹, Ellen Cahill¹, Joann Carlson¹, Yue Hao¹, Daniel Horton¹, Vivien Hsu¹, Editt Rodriguez¹, Christian Salazar³, Cynthia Salvant¹ and Lawrence Kleinman¹, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Department of Communication, New Brunswick, NJ, ³NYU Dept. of Epi. and Health Promotion, New York, NY
Background/Purpose: COVID-19 can lead to severe and life-threatening complications, which is particularly unnerving for patients with autoimmune disease (AID) on immunosuppressive therapy. Telemedicine has enabled…
Abstract Number: 1630 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
Lauren Covert¹, Mara Becker², Rebecca Sadun¹ and Heather Van Mater¹, ¹Duke University, Durham, NC, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a recently defined post-infectious phenomena associated with coronavirus disease 2019 (COVID-19). We assessed the demographics, clinical characteristics,…
Abstract Number: 0089 • ACR Convergence 2021
SARS-CoV-2 Seroprevalence and Seroconversion in a Systemic Lupus Erythematosus Cohort and Comparison to General Population Controls
Hannah Mathew¹, May Choi², Katherine Buhler¹, Ann Clarke¹, Xenia Gukova¹, Francesca Cardwell³ and Marvin Fritzler¹, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ³University of Waterloo, Waterloo, ON, Canada
Background/Purpose: At the outset of the SARS-CoV-2 pandemic, it was speculated that SLE patients may be at significant risk of developing COVID-19 due to underlying…
Abstract Number: 0106 • ACR Convergence 2021
COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study
Mousa Albalwi, Ben Brintz, Srinivasan Beddhu, Guo Wei and Julie Thomas, University of Utah, Salt Lake City, UT
Background/Purpose: Following SARS-CoV-2 infection, patients with rheumatic diseases seem to have similar or slightly poorer outcomes compared with those without rheumatic disease. However, robust data…
Abstract Number: 0267 • ACR Convergence 2021
Psychosocial and Health Measures in Systemic Lupus Erythematosus: Before and During the COVID-19 Pandemic in the Georgian’s Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao¹, S Sam Lim² and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Disruptions of routines or livelihood and worry during the COVID-19 pandemic may have impacted systemic lupus erythematosus (SLE) patients in multiple ways. We explored…
Abstract Number: 0856 • ACR Convergence 2021
Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
Alexander Hall¹, Michael Trevisonno¹, Elizabeth Murray¹, Omoakhe Tisor¹, Emily Stanford¹, Jacob Gaines¹, Noor Anvery¹ and Ellen Ginzler², ¹SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: The risk of COVID-19 infection among patients with Systemic Lupus Erythematosus (SLE) is poorly understood. Patients with SLE often take medications which modulate the…
Abstract Number: 1013 • ACR Convergence 2021
SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children
Kate Webb¹, Thandeka Moyo-Gwete², Simon Mendelsohn³, Claire Butters⁴, Simone Richardson⁵, Heidi Facey-Thomas⁴, Debbie Abrahams⁴, Mashudu Madzivhandila⁵, Zanele Makhado⁵, Frances Ayres⁵, William Horsnell⁶, Neilia Manamela⁵, Richard Baguma³, Stanley Kimbung Mbandi³, Mzwandile Erasmus³, Thomas Scriba³, Liesl Zühlke⁷, Penny Moore⁵, George Kassiotis⁸ and Christiaan Scott⁴, ¹Paediatric Rheumatology University of Cape Town/ Francis Crick Institute, Cape Town, South Africa, ²National Institute of Communicable Diseases/University of Witwatersrand, Johannesburg, South Africa, ³South African TB vaccine initiative, IIDM, University of Cape Town, Cape Town, South Africa, ⁴Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ⁵National Institute of Communicable Diseases/University of Witwatersrand, Cape Town, South Africa, ⁶University of Cape Town, Cape Town, South Africa, ⁷Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, ⁸Retroviral Immunology, Francis Crick Institute, London, United Kingdom
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a severe disease that affects a small proportion of children exposed to Severe Acute Respiratory Syndrome Coronavirus…
Abstract Number: 1445 • ACR Convergence 2021
Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)
Namrata Singh¹, Chen Hu², Vithal Madhira², Kate Fitzgerald², Timothy Bergquist³, Kayte Anderson², Amy Olex⁴, Rena Patel⁵ and Jasvinder Singh⁶, ¹University of Washington, Bellevue, WA, ²Johns Hopkins, Baltimore, MD, ³Sage Bionetworks, Seattle, WA, ⁴Virginia Commonwealth University, Richmond, VA, ⁵UW, Seattle, WA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with Rheumatoid arthritis (RA) are at a potentially increased risk of SARS-CoV-2 infection, and immunosuppressive or biologic drugs used to treat RA might…
Abstract Number: 1542 • ACR Convergence 2021
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
Andrew Laster¹, Gordon Lam¹, Sarah McCarter¹, Heather Gladue², Ahmad Kashif¹, Erin Siceloff¹, Victoria Lackey², Cheryl Robertson², Ashley Toci¹ and Leonard Calabrese³, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…
Abstract Number: 1560 • ACR Convergence 2021
A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome
Anand Kumthekar¹ and Bibi Ayesha², ¹Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center, Bronx, NY
Background/Purpose: Coronavirus disease (COVID-19) patients can progress to a state of unregulated inflammation called cytokine storm syndrome (CSS). A multi-disciplinary approach is needed to identify…
Abstract Number: 1602 • ACR Convergence 2021
Factors Associated with COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Brandon Schneider², Jonah Levine¹, Huong Do¹, Caroline Siegel¹, Vivian Bykerk³, Candace Feldman⁴, Deanna Jannat-Khah¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: COVID-19 vaccination is particularly important for patients with systemic rheumatic diseases (SRDs), who may be at increased risk of infection with SARS-CoV-2 and of…
Abstract Number: 1637 • ACR Convergence 2021
Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
Eric Kok, Martha Curry, Andrea Ramirez, Eyal Muscal and Marietta DeGuzman, Baylor College of Medicine, Houston, TX
Background/Purpose: Infection with novel coronavirus (COVID-19) in children, unlike adults, is generally asymptomatic or causes mild disease although some may develop severe illness. In particular,…
Abstract Number: 0090 • ACR Convergence 2021
Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial
Sebastián C Rodriguez-García¹, Isidoro Gonzalez-Alvaro¹, Francisco Abad-Santos², Azucena Bautista-Hernández³, Lucio García-Fraile³, Juan Pablo Baldivieso-Achá⁴, Jesús Sanz-Sanz³ and Rosario Garcia de Vicuña¹, ¹Rheumatology Service. La Princesa University Hospital, Madrid, Spain, ²Clinical Pharmacology Service. Clinical Research and Clinical Trials Unit. La Princesa University Hospital, Madrid, Spain, ³Division of Infectious Diseases, Internal Medicine Service. La Princesa University Hospital, Madrid, Spain, ⁴Rheumatology Department. La Princesa University Hospital, Madrid, Spain
Background/Purpose: Many uncertainties remain for IL-6 blockers on the management of COVID-19 such as the optimal time of intervention, the schedule of administration and predictors…
Abstract Number: 0107 • ACR Convergence 2021
Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries
Lina El Kibbi¹, Mona Metawee¹, Ihsane Hmamouchi², Nizar Abdulateef³, Hussein Halabi⁴, Mervat Eissa⁵, Manal El Rakawi⁶, Basel Masri⁷, Fatemah Abutiban⁸, Wafa Hamdi⁹, Asal Adnan³, Antonella Abi Najm¹⁰, Renaud Felten¹¹, Laurent Arnaud¹¹ and Nelly Ziade¹², ¹Specialized Medical Center, Riyadh, Saudi Arabia, ²Rheumatology Unit, Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, ³Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq, ⁴King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, ⁵Cairo University, Cairo, Egypt, Cairo, Egypt, ⁶Rheumatology Department, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, ⁷Jordan Hospital, Amman, Jordan, ⁸Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, Kuwait City, Kuwait, ⁹Rheumatology Department, Kassab Institute of Orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia, ¹⁰Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, ¹¹Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ¹²Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon
Background/Purpose: The first COVID-19 vaccines were authorized in December 2020. However, their acceptability remains debated and has never been evaluated in patients with chronic rheumatic…
Abstract Number: 0390 • ACR Convergence 2021
Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Kimberly Showalter¹, Jessica Gordon¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: COVID-19 vaccination is recommended for individuals with rheumatic diseases, yet data are limited regarding vaccine safety in this population, particularly among those with rare…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].